List of EpicentRx patents

List of EpicentRx patents

List of Denka (company) patents

List of Nps Pharmaceuticals patents

List of Malibu Boats patents

List of companies in General Global Capital's investment portfolio

Open access venture capital investors

Patents where

Current Assignee

Name

is

EpicentRx

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11510901 Methods and compositions utilizing RRx-001 combination therapy for radioprotection	Patent 11510901 was granted and assigned to EpicentRx on November, 2022 by the United States Patent and Trademark Office.	EpicentRx	EpicentRx		United States Patent and Trademark Office	11510901	November 29, 2022
	‌ US Patent 11834492 Human IL-10 receptor alpha fusion proteins	Patent 11834492 was granted and assigned to EpicentRx on December, 2023 by the United States Patent and Trademark Office.	EpicentRx	EpicentRx		United States Patent and Trademark Office	11834492	December 5, 2023
	‌ US Patent 11008287 Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine	Patent 11008287 was granted and assigned to EpicentRx on May, 2021 by the United States Patent and Trademark Office.	EpicentRx	EpicentRx		United States Patent and Trademark Office	11008287	May 18, 2021
	‌ US Patent 11576895 Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone	Patent 11576895 was granted and assigned to EpicentRx on February, 2023 by the United States Patent and Trademark Office.	EpicentRx	EpicentRx		United States Patent and Trademark Office	11576895	February 14, 2023
	‌ US Patent 10543208 Treatment of gliomas using organonitro compound combination therapy	Patent 10543208 was granted and assigned to EpicentRx on January, 2020 by the United States Patent and Trademark Office.		EpicentRx		United States Patent and Trademark Office	10543208	January 28, 2020
	‌ US Patent 10342778 Treatment of brain metastases using organonitro compound combination therapy	Patent 10342778 was granted and assigned to EpicentRx on July, 2019 by the United States Patent and Trademark Office.		EpicentRx		United States Patent and Trademark Office	10342778	July 9, 2019
	‌ US Patent 11160784 Treatment of brain metastases using organonitro compound combination therapy	Patent 11160784 was granted and assigned to EpicentRx on November, 2021 by the United States Patent and Trademark Office.	EpicentRx	EpicentRx		United States Patent and Trademark Office	11160784	November 2, 2021
	‌ US Patent 11253608 Recombinant adenoviruses carrying transgenes	Patent 11253608 was granted and assigned to EpicentRx on February, 2022 by the United States Patent and Trademark Office.	EpicentRx	EpicentRx		United States Patent and Trademark Office	11253608	February 22, 2022
	‌ US Patent 11701351 Treatment of gliomas using organonitro compound combination therapy		EpicentRx	EpicentRx		United States Patent and Trademark Office	11701351	July 18, 2023
	‌ US Patent 11999973 Method for producing recombinant oncolytic adenovirus with modified E1a cancer-specific promoter	Patent 11999973 was granted and assigned to EpicentRx on June, 2024 by the United States Patent and Trademark Office.	EpicentRx	EpicentRx		United States Patent and Trademark Office	11999973	June 4, 2024
	‌ US Patent 11660286 Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products		EpicentRx	EpicentRx		United States Patent and Trademark Office	11660286	May 30, 2023
	‌ US Patent 12109348 Medication infusion devices, systems, and methods	Patent 12109348 was granted and assigned to EpicentRx on October, 2024 by the United States Patent and Trademark Office.	EpicentRx	EpicentRx		United States Patent and Trademark Office	12109348	October 8, 2024
	‌ US Patent 11744859 Compositions and methods for parenteral administration of therapeutic agents	Patent 11744859 was granted and assigned to EpicentRx on September, 2023 by the United States Patent and Trademark Office.	EpicentRx	EpicentRx		United States Patent and Trademark Office	11744859	September 5, 2023

13 results

0 selected

13 results

0 selected